An integrative paradigm to impart quality to correlative science
Open Access
- 16 March 2010
- journal article
- review article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 8 (1) , 26
- https://doi.org/10.1186/1479-5876-8-26
Abstract
Correlative studies are a primary mechanism through which insights can be obtained about the bioactivity and potential efficacy of candidate therapeutics evaluated in early-stage clinical trials. Accordingly, well designed and performed early-stage correlative studies have the potential to strongly influence further clinical development of candidate therapeutic agents, and correlative data obtained from early stage trials has the potential to provide important guidance on the design and ultimate successful evaluation of products in later stage trials, particularly in the context of emerging clinical trial paradigms such as adaptive trial design.This publication has 38 references indexed in Scilit:
- Bayesian clinical trials at the University of Texas M. D. Anderson Cancer CenterClinical Trials, 2009
- Biomarkers of response and resistance to antiangiogenic therapyNature Reviews Clinical Oncology, 2009
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant ChemotherapyClinical Pharmacology & Therapeutics, 2009
- Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agentsDrug Resistance Updates, 2008
- Adaptive design methods in clinical trials – a reviewOrphanet Journal of Rare Diseases, 2008
- Antiangiogenic Therapy in Malignant Glioma: Promise and ChallengeCurrent Pharmaceutical Design, 2007
- Adaptive trial design.2007
- A Clinical Development Paradigm for Cancer Vaccines and Related BiologicsJournal of Immunotherapy, 2007
- Biomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development: Quantification of Emerging Protein BiomarkersPublished by Elsevier ,2006
- Pharmacodynamic Biomarkers for Molecular Cancer TherapeuticsPublished by Elsevier ,2006